Manning & Napier Group's BMRN Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 170 shares of BioMarin Pharmaceutical Inc. (BMRN) worth $9,207, representing 0.00% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Manning & Napier Group has maintained a long-term strategic position in BMRN, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2016, adding 1.89 M shares. Largest reduction occurred in Q3 2025, reducing 1.15 M shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Manning & Napier Group
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2014 | +171,510 | New Buy | 171,510 | $68.20 |
| Q2 2014 | +72,550 | Add 42.30% | 244,060 | $62.21 |
| Q3 2014 | +44,120 | Add 18.08% | 288,180 | $72.15 |
| Q1 2015 | -288,180 | Sold Out | 288,180 | $0.00 |
| Q2 2016 | +139,920 | New Buy | 139,920 | $77.79 |
| Q3 2016 | +2,490 | Add 1.78% | 142,410 | $92.51 |
| Q4 2016 | +1.89 M | Add 1324.01% | 2.03 M | $82.84 |
| Q1 2017 | -335,460 | Reduce 16.54% | 1.69 M | $87.78 |
| Q2 2017 | +426,016 | Add 25.17% | 2.12 M | $90.82 |
| Q3 2017 | -52,776 | Reduce 2.49% | 2.07 M | $93.07 |
| Q4 2017 | +1.98 M | Add 0.00% | 1.98 M | $89.17 |
| Q1 2018 | -64,419 | Reduce 3.25% | 1.92 M | $81.07 |
| Q2 2018 | -32,785 | Reduce 1.71% | 1.88 M | $94.20 |
| Q3 2018 | -479,145 | Reduce 25.44% | 1.4 M | $96.97 |
| Q4 2018 | -404,610 | Reduce 28.81% | 999,918 | $85.15 |
| Q1 2019 | -88,959 | Reduce 8.90% | 910,959 | $88.83 |
| Q2 2019 | -184,898 | Reduce 20.30% | 726,061 | $85.65 |
| Q3 2019 | +4,032 | Add 0.56% | 730,093 | $67.40 |
| Q4 2019 | +370,098 | Add 50.69% | 1.1 M | $84.55 |
| Q1 2020 | -49,833 | Reduce 4.53% | 1.05 M | $84.50 |
| Q2 2020 | -79,835 | Reduce 7.60% | 970,523 | $123.34 |
| Q3 2020 | +162,195 | Add 16.71% | 1.13 M | $76.08 |
| Q4 2020 | -49,358 | Reduce 4.36% | 1.08 M | $87.69 |
| Q1 2021 | +621,482 | Add 57.37% | 1.7 M | $75.51 |
| Q2 2021 | +22,542 | Add 1.32% | 1.73 M | $83.44 |
| Q3 2021 | +15,597 | Add 0.90% | 1.74 M | $77.29 |
| Q4 2021 | -5,922 | Reduce 0.34% | 1.74 M | $88.35 |
| Q1 2022 | -31,704 | Reduce 1.83% | 1.71 M | $77.10 |
| Q2 2022 | -758,954 | Reduce 44.50% | 946,401 | $82.87 |
| Q3 2022 | -14,610 | Reduce 1.54% | 931,791 | $84.77 |
| Q4 2022 | -57,225 | Reduce 6.14% | 874,566 | $103.49 |
| Q1 2023 | +226,152 | Add 25.86% | 1.1 M | $97.24 |
| Q2 2023 | +37,041 | Add 3.37% | 1.14 M | $86.68 |
| Q3 2023 | +1,193 | Add 0.10% | 1.14 M | $88.48 |
| Q4 2023 | +6,161 | Add 0.54% | 1.15 M | $96.42 |
| Q1 2024 | +8,672 | Add 0.76% | 1.15 M | $87.34 |
| Q3 2025 | +170 | New Buy | 170 | $54.16 |
Manning & Napier Group's BioMarin Pharmaceutical Investment FAQs
Manning & Napier Group first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q1 2014, acquiring 171,510 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held BioMarin Pharmaceutical Inc. (BMRN) for 47 quarters since Q1 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q4 2017, adding 1,980,877 shares worth $176.63 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 170 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $9,207. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 2,118,486 shares, as reported at the end of Q2 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.